Jump to contents

Researcher Information

last modified：2024/12/16

Associate Professor　TAKEUCHI, Shinji

Mail

Faculty, Affiliation

University Hospital

College and School Educational Field


Laboratory

Academic Background

Career

Year & Month of Birth

1978/10

Academic Society

Award

Specialities

Speciality Keywords

Research Themes

Books

Papers

  • 　Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.　Shinji Takeuchi,Kenichi Yoshimura,Tadami Fujiwara,Masahiko Ando,Shinobu Shimizu,Katsuhiko Nagase,Yoshinori Hasegawa,Toshiaki Takahashi,Nobuyuki Katakami,Akira Inoue,Seiji Yano　The journal of medical investigation : JMI　64　3.4　321　2017
  • 　Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.　Shinji Takeuchi,Toshinori Murayama,Kenichi Yoshimura,Takahiro Kawakami,Shizuko Takahara,Yasuhito Imai,Yoshikazu Kuribayashi,Katsuhiko Nagase,Koichi Goto,Makoto Nishio,Yoshinori Hasegawa,Miyako Satouchi,Katsuyuki Kiura,Takashi Seto,Seiji Yano　The journal of medical investigation : JMI　64　3.4　317　2017
  • 　Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.　Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Shigeki Nanjo,Kenji Kita,Tadaaki Yamada,Eiji Hara,Hiroshi Nishihara,Hisanori Uehara,Seiji Yano　International journal of cancer　138　5　1281　2016/03/01
  • 　Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.　Hirokazu Taniguchi,Shinji Takeuchi,Koji Fukuda,Takayuki Nakagawa,Sachiko Arai,Shigeki Nanjo,Tadaaki Yamada,Hiroyuki Yamaguchi,Hiroshi Mukae,Seiji Yano　Cancer science　108　1　53　2017/01
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano　Cancer research　73　8　2428　2013/04/15

show all

  • 　Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.　Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Koichi Goto,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　27　5　1410　2020/12/11
  • 　Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).　Shinji Takeuchi,Noriko Yanagitani,Takashi Seto,Yoshihiro Hattori,Kadoaki Ohashi,Masahiro Morise,Shingo Matsumoto,Kiyotaka Yoh,Koichi Goto,Makoto Nishio,Shizuko Takahara,Takahiro Kawakami,Yasuhito Imai,Kenichi Yoshimura,Azusa Tanimoto,Akihiro Nishiyama,Toshinori Murayama,Seiji Yano　Translational lung cancer research　10　1　314　2021/01
  • 　A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.　Hiroyuki Yasuda,Eiki Ichihara,Jun Sakakibara-Konishi,Yoshitaka Zenke,Shinji Takeuchi,Masahiro Morise,Katsuyuki Hotta,Mineyoshi Sato,Shingo Matsumoto,Azusa Tanimoto,Reiko Matsuzawa,Katuyuki Kiura,Yuta Takashima,Seiji Yano,Junji Koyama,Takahiro Fukushima,Junko Hamamoto,Hideki Terai,Shinnosuke Ikemura,Ryo Takemura,Koichi Goto,Kenzo Soejima　Lung cancer (Amsterdam, Netherlands)　162　140　2021/12
  • 　Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Kenji Kita,Azusa Tanimoto,Akihiro Nishiyama,Seiji Yano　Cancer science　111　7　2374　2020/07
  • 　MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.　Akihiro Nishiyama,Shinji Takeuchi,Yuta Adachi,Sakiko Otani,Azusa Tanimoto,Motoko Sasaki,Shingo Matsumoto,Koichi Goto,Seiji Yano　Cancer science　111　10　3813　2020/07/31
  • 　Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.　Shinji Takeuchi,Tetsunari Hase,Shinobu Shimizu,Masahiko Ando,Akito Hata,Haruyasu Murakami,Takahiro Kawakami,Katsuhiko Nagase,Kenichi Yoshimura,Tadami Fujiwara,Azusa Tanimoto,Akihiro Nishiyama,Sachiko Arai,Koji Fukuda,Nobuyuki Katakami,Toshiaki Takahashi,Yoshinori Hasegawa,Tun Kiat Ko,S Tiong Ong,Seiji Yano　Cancer science　111　2　561　2020/02
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Ryohei Katayama,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Takayuki Nakagawa,Hirokazu Taniguchi,Takeshi Suzuki,Tadaaki Yamada,Hiroshi Nishihara,Hironori Ninomiya,Yuichi Ishikawa,Satoko Baba,Kengo Takeuchi,Atsushi Horiike,Noriko Yanagitani,Makoto Nishio,Seiji Yano　Cancer research　79　7　1658　2019/04/01
  • 　Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.　Sachiko Arai,Shinji Takeuchi,Koji Fukuda,Hirokazu Taniguchi,Akihiro Nishiyama,Azusa Tanimoto,Miyako Satouchi,Kaname Yamashita,Koshiro Ohtsubo,Shigeki Nanjo,Toru Kumagai,Ryohei Katayama,Makoto Nishio,Mei-Mei Zheng,Yi-Long Wu,Hiroshi Nishihara,Takushi Yamamoto,Mitsutoshi Nakada,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　15　5　752　2020/05
  • 　Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.　Koji Fukuda,Sakiko Otani,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Katsuhiko Naoki,Seiji Yano　Cancer science　112　9　3784　2021/06/19
  • 　Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.　Daisuke Kotani,Atsuo Takashima,Takeshi Kato,Taroh Satoh,Toshiki Masuishi,Yoshito Komatsu,Manabu Shiozawa,Taito Esaki,Naoki Izawa,Shinji Takeuchi,Hideaki Bando,Satoru Iwasa,Hiroko Hasegawa,Toshifumi Yamaguchi,Hiroya Taniguchi,Yasunori Ushida,Toshiya Oizaki,Chiaki Inoue,Takayuki Yoshino　Clinical colorectal cancer　2024/03/09
  • 　STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.　Naohiro Yanagimura,Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Azusa Tanimoto,Akihiro Nishiyama,Naohisa Ogo,Hiroyuki Takahashi,Akira Asai,Satoshi Watanabe,Toshiaki Kikuchi,Seiji Yano　NPJ precision oncology　6　1　11　2022/02/28
  • 　Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.　Chiaki Suzuki,Akihiro Nishiyama,Sachiko Arai,Shoichiro Tange,Atsushi Tajima,Azusa Tanimoto,Koji Fukuda,Yohei Takumi,Hiroshi Kotani,Shinji Takeuchi,Naohiro Yanagimura,Koushiro Ohtsubo,Norio Yamamoto,Koichi Omori,Seiji Yano　Cancer science　113　7　2323　2022/04/01
  • 　FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.　Yukata Fujiwara,Yasutoshi Kuboki,Masayuki Furukawa,Nobumasa Mizuno,Hiroki Hara,Tatsuya Ioka,Makoto Ueno,Yasuo Takahashi,Shunji Takahashi,Shinji Takeuchi,Christine Lihou,Tao Ji,Chenwei Tian,Toshio Shimizu　Cancer medicine　12　9　10597　2023/03/31
  • 　Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.　Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Sachiko Arai,Satoshi Takagi,Genichiro Ishii,Atsushi Ochiai,Shotaro Iwakiri,Kazumi Itoi,Hisanori Uehara,Hiroshi Nishihara,Naoya Fujita,Seiji Yano　Cancer science　108　4　696　2017/04
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S.　PLoS One.　8　5　e62104　2013/05/14
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.　Cancer Res.　73　8　2428-34　2013/04/15

Conference Presentations

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○2022「ALK肺がんのアポトーシス抵抗性因子を標的とした新規治療の開発」(2020-2022)　
○「miR-201sを標的とした肺癌のEMTに起因するTKI耐性克服治療の開発」(2018-2020)　
○「アポトーシス抵抗性に起因する変異型選択的EGFR-TKI耐性克服治療の開発」(2017-2019)　
○「EGFR変異肺癌のアポトーシス抵抗性に起因する次世代型EGFR-TKI耐性の克服」(2017-2019)　
○「EGFR変異肺癌のBIM遺伝子多型に起因するEGFR-TKI耐性克服治療の開発」(2013-2014)
○「Rasシグナル活性化変異を有する原発性肺癌を標的とした新規治療法の開発」(2011-2012)　

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

Classes (Graduate Schools)

○Seminar on Clinical Oncology(2017)
○Seminar on Clinical Oncology(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top